Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Crawford & Company (NYSE: CRD-A, CRD-B) has released a report titled “Super El Niño – Potential Impacts for Agriculture in the UK,” outlining how a particularly strong El Niño could increase weather-related risks for UK farmers and agricultural insurers.
According to Crawford & Company, heavier rainfall, flooding, storms and compound events of drought followed by flooding could raise insured losses, complicate claims and lengthen loss tails. The report also notes potential secondary effects such as crop establishment problems, soil erosion, higher feed and input costs, greater livestock disease pressures and increased claims complexity, reinforcing the need for resilience measures and proactive risk management by both farmers and insurers.
Agilent (NYSE: A) received European Union certification for its PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to help identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA (pembrolizumab).
According to Agilent, this is the eighth CE-marked companion diagnostic indication for PD-L1 IHC 22C3 pharmDx in the EU. The assay supported patient selection in the KEYNOTE-B96/ENGOT-ov65 trial in the platinum-resistant setting and is already indicated in the EU for several other tumor types, including NSCLC, esophageal, cervical, HNSCC, TNBC, gastric/GEJ adenocarcinoma, and urothelial carcinoma.
Crawford & Company announced that Matthew Solorio, a national general adjuster in its Global Technical Services division, has been named to Insurance Business America’s 2026 Rising Stars list, which honors leading U.S. insurance professionals under 40 for technical expertise, leadership and innovation.
Solorio manages complex, often multimillion-dollar commercial and residential property claims nationwide, coordinating multidisciplinary teams to resolve large-loss, catastrophe and technical claims. He also co-leads initiatives to improve claims workflows and operational efficiency, exemplifying Crawford’s depth of technical talent in complex claims handling.
Agilent Technologies (NYSE: A) received U.S. FDA approval for its PD‑L1 IHC 28‑8 pharmDx assay as a companion diagnostic in esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma. The test identifies patients whose tumors express PD‑L1 (Combined Positive Score [CPS] ≥ 1) and who may be eligible for treatment with Bristol Myers Squibb’s OPDIVO (nivolumab) or OPDIVO QVANTIG (nivolumab and hyaluronidase‑nvhy).
According to Agilent, PD‑L1 IHC 28‑8 pharmDx (Code SK005) is FDA‑approved for exclusive use on the Agilent Autostainer Link 48 platform and was developed in partnership with Bristol Myers Squibb within the OPDIVO clinical program. The company notes that CheckMate‑648 and CheckMate‑649 studies showed improved overall and progression‑free survival with OPDIVO‑based regimens in these tumors, underscoring the role of accurate PD‑L1 testing. Agilent positions this approval as reinforcing its leadership in immunohistochemistry‑based diagnostics and drug‑diagnostic co‑development, supporting precision oncology in cancers that together account for over 1.4 million new cases and more than 1.1 million deaths globally each year.
Agilent (NYSE:A) expanded its Altura HPLC column portfolio with new Altura size exclusion (SEC) and Altura PLRP-S columns for biotherapeutic analysis.
The columns use Ultra Inert technology to improve peak shape, sensitivity, aggregate recovery and conditioning across peptides, proteins, oligonucleotides, antibody-drug conjugates and other complex modalities, and are available globally.
Crawford & Company (NYSE:A) renewed its corporate membership with RISE (Rising Insurance Star Executives), underscoring a commitment to developing early-career insurance professionals. RISE offers mentorship, education, networking and leadership programs that help build future insurance leaders.
Crawford highlights this membership as part of a broader talent strategy that includes Broadspire’s Early Career and Global Technical Services’ Protégé Programs, internships, university partnerships and structured training through Crawford Educational Services.
Agilent (NYSE:A) launched xCELLigence RTCA eSight AI, an AI-powered software module for its RTCA eSight instrument. The module automates label-free imaging analysis, reducing manual cell segmentation and parameter tuning while supporting standardized, dual imaging and impedance readouts from the same cells.
It targets drug discovery and high-throughput biopharma research and builds on Agilent’s 2025 revenue base of $6.95 billion and approximately 18,000 employees worldwide.
Agilent (NYSE:A) completed its acquisition of Biocare Medical, a global clinical pathology provider, from an investor group led by Excellere Partners and GHO Capital Partners. Biocare joins Agilent’s Life Sciences and Diagnostics Markets Group.
According to Agilent, the deal is expected to be accretive to top-line growth, margin profile and non-instrument revenue mix in year one, and to EPS about 12 months after close. The company plans to outline the expected FY2026 financial impact in its third-quarter earnings release.
Crawford (NYSE:A) announced a leadership transition in its Middle East operations and new senior hires in the UAE.
Regional director Vic Noble will retire at the end of July 2026. Christopher Wylie becomes regional director from 22 June 2026, and senior adjusters Chris Burley and Steve Smith join in the UAE.
Agilent Technologies (NYSE:A) announced a collaboration with OpenAI and Boston Consulting Group (BCG) to deploy artificial intelligence across its products, operations, and customer workflows.
Initial AI use cases focus on enhancing customer experience and speeding the new product pipeline, with plans to expand efforts over the next 6–12 months.